DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Dose-response, 73–74, 74f
Dose-response curve, 73, 74f
Dothiepin, potencies at human
transporters for monamine
neurotransmitters, 406t
DOUBLE ANTIBIOTIC OINTMENT, 1817
Double product, 766–767
DOVONEX (calcipotriene), 1813
Doxacurium
characteristics of, 264t
dosing of, 265t
Doxapram, 1058
Doxasozin
adrenergic receptors and, 206t
pharmacokinetics of, 1833t
Doxazosin, 306f, 307
adverse effects and side effects of,
780
as antihypertensive agent, 774t,
779–780
Doxepin, 921t, 923
anti-pruritic effects, 1816
disposition, 409t
dose and dosage forms of, 400t
pharmacokinetics of, 1816t, 1833t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors, 410t
side effects of, 400t, 1816
Doxercalciferol, 1291, 1292f
DOXIL (doxorubicin), 1823
Doxorubicin, 1668t–1670t
ABC transporters and, 105t, 106t
liposomal, for Kaposi sarcoma, 1823
pharmacokinetics of, 1834t
Doxycycline
for acne, 1817
for Chlamydia, 1842t
for granuloma inguinale, 1842t
for helminth infections, 1454
for lymphogranuloma venereum,
1842t
for malaria, 1391t
for non-gonococcal urethritis, 1842t
for pelvic inflammatory disease,
1842t
pharmacokinetics of, 1834t
DPDPE, actions and selectivities of,
485t
DPP-4 inhibitors, 1264–1265
Dracunculus medinensis, 1447
DRAMAMINE (dimenhydrinate), 921t
DRIs. See Renin inhibitors, direct
Droloxifene, 1756
Dronabinol, 1344–1345
pharmacokinetics of, 1834t
therapeutic uses of, as antinausea
agent, in cancer
chemotherapy, 1344t
Dronedarone
adverse effects and side effects of,
840
dosage and administration of, 835t
drug interactions with, 840
electrophysiological actions of, 829t
pharmacokinetics of, 835t
pharmacology of, 840
structure of, 840
Droperidol, arrhythmias caused by,
832
Drosperinone, 1833, 1834
Drotrecogin alfa, 860
Droxicam, 990
Drug(s)
absorption of (See Absorption of
drugs)
cutaneous delivery, 1803, 1804f
definition of, 3
development of (See Development
of drugs)
distribution of, 23–25 (See also
Distribution of drugs)
as entitlement, 10
excretion of (See Excretion of drugs)
histamine release by, 914
history of, 3–4
as inventions, 3
sources of, 4–5
topical
absorption, mechanisms of, 1804–
1805
preferable characteristics, 1805
“Drugability,” 4, 6
Drug abuse and addiction
agent variables in, 650–651
amphetamines, 663
barbiturates, 657
benzodiazepines, 656–657
caffeine, 663
clinical issues, 654–666
cocaine, 661–663
environmental variables in, 651–652
ethanol, 654–656
host variables in, 651
inhalants, 666
marijuana, 663–664
nicotine, 657–658
opioids, 658–661
Drug abuse and addiction (Cont.):
origins of, 649–652
pharmacological phenomena and,
652–653
physical dependence and, 653–654
psychedelic agents, 664–666
sensitization and, 653
tolerance and, 652
user variables in, 651
withdrawal syndrome and, 653–654
Drug Abuse Warning Network
(DAWN), 80
Drug action, targets of, 5–6
Drug advertising, 1883
Drug classes, choosing within, 1802
Drug design, structure-activity
relationships and, 43–44
Drug-drug interactions, 77–78
CYPs and, 129–130
hepatic transporters and, 110
Drug elimination
enhancing, 85
poisoning and, 75
Drug elimination, ABC transporters in,
107
Drug Price Competition and Patent
Term Restoration Act of
1978, 12
Drug resistance, transporters and, 91,
103
Dry eye, 1773
Dry-powder inhalers, 1035
D-Serine, 103t
DSLET, actions and selectivities, 485t
DTC. See Direct-to-consumer (DTC)
advertising
DUAC (antibiotic-benzoyl peroxide
combination), 1817
Dubin-Johnson syndrome, 104t
Duloxetine
dosage of, 402t
pharmacokinetics of, 1835t
side effects of, 402t
DURICEF (cefadroxil), 1494t
Dutasteride, 1205
pharmacokinetics of, 1835t
Dyes, 4
in ocular diagnosis, 1793
DYMELOR (acetohexamide), 1257t
DYNACIRC (isradipine), 762t
DYNASTAT (parecoxib), 991–992
Dynorphin(s)
A, actions and selectivities of, 485t
B, actions and selectivities of, 485t
DYRENIUM (amiloride), 690t
2021
INDEX